好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Dysferlinopathy as Cause of Long-term Asymptomatic HyperCKemia and Myalgia
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (5:00 PM-6:00 PM)
11-016

To describe rare dysferlinopathy phenotypes.

Dysferlin (DYSF) has a crucial role in sarcolemmal repair. DYSF mutations commonly manifest with limb-girdle muscular dystrophy (LGMDR2) or distal myopathy affecting posterior leg compartment muscles (Miyoshi myopathy) or less frequently, tibialis anterior. “Pseudometabolic” phenotype and asymptomatic hyperCKemia are exceedingly rare dysferlinopathy presentations with very few patients reported in the literature.

Review of clinical, serological, genetic, myopathological, and radiological studies in 3 patients with rare dysferlinopathy phenotypes.

Patient 1 is a 51-year-old female with exercise-induced myalgia predominantly affecting calf muscles for 7 years. She was known to have asymptomatic hyperCKemia (CK 812-2,223 U/L) for at least 22 years prior to symptom onset. She had normal muscle strength and mild calf enlargement. She carries two DYSF variants, c.2163-2A>G (pathogenic) and c.866C>G, p.Ser289Cys (VUS), unknown if heteroallelic. Muscle biopsy showed nuclei internalization and lack of dysferlin immunoreactivity. Patient 2 is a 20-year-old male, football player, with asymptomatic CK elevation (729-2,645 U/L). He had normal muscle strength but mild atrophy of calf muscles. He harbors two DYSF variants in trans, c.6008G>A, p.Gly2003Asp (pathogenic) and c.854C>T, p.Thr285Met (VUS). Muscle biopsy showed no myopathic changes but reduced dysferlin immunoreactivity, which was confirmed by western blot. Patient 3 is a 58-year-old female with asymptomatic hyperCKemia (CK: 249-2,096 U/L) for 2 years.  She had normal strength and normal thigh muscle MRI. She has two DYSF variants in trans, c.2517del, p.Met840Trpfs*108 (pathogenic) and c.6058C>T, p.Arg2020Cys (VUS). Muscle biopsy showed minimal myopathic changes and attenuated dysferlin immunoreactivity. Needle EMG was normal in all 3 patients. 

These patients highlight rare manifestations of dysferlinopathy and underscore the importance of considering dysferlinopathy in the differential diagnosis of metabolic myopathies and asymptomatic hyperCKemia.

Authors/Disclosures
Ikreet Cheema, MD
PRESENTER
Dr. Cheema has nothing to disclose.
Jacob Goodwin, MD (Cuyuna Regional Medical Center) Dr. Goodwin has nothing to disclose.
Teerin Liewluck, MD, FAAN (Department of Neurology, Mayo Clinic) Dr. Liewluck has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Liewluck has received publishing royalties from a publication relating to health care.
Bob Bucelli, MD, PhD (Washington University) Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen . Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bucelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Bucelli has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Hamilton Weber. Dr. Bucelli has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for O'Bryan Brown and Toner. Dr. Bucelli has stock in Neuroquestions.com. An immediate family member of Dr. Bucelli has stock in Neuroquestions.com. The institution of Dr. Bucelli has received research support from Biogen. The institution of Dr. Bucelli has received research support from Ionis.
Alan Pestronk, MD, FAAN (Washington University in Saint Louis - Neurology) The institution of Dr. Pestronk has received research support from Jain. The institution of Dr. Pestronk has received research support from Fulcrum. The institution of Dr. Pestronk has received research support from Argenyx. The institution of Dr. Pestronk has received research support from NeuroNext.
Margherita Milone, MD, FAAN (Mayo Clinic) Dr. Milone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cartesian Therapeutics. Dr. Milone has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics, AAN. The institution of Dr. Milone has received research support from Mayo Clinic, CCaTS-CBD. The institution of Dr. Milone has received research support from Mayo Clinic, SGP Award. The institution of Dr. Milone has received research support from MDA for Care Center grant. The institution of Dr. Milone has received research support from Regenerative medicine Minnesota.